|
Bruce P. Babbitt is currently the Principal Consultant, Drug Development Consulting at Parexel Consulting in Waltham, MA. From June 2000 through September 2004, Dr. Babbitt was a Senior Regulatory Consultant, Head of Biotechnology Consulting Services, Worldwide Regulatory Affairs at Parexel. His primary responsibilities include the formation of drug development and regulatory strategies for biotech clients developing a broad range of small molecule drugs and biologics, with a major focus on early-stage drug development activities required by the FDA for transition from pre-clinical studies to first-in-man Phase I/II clinical trials. Prior to Parexel, Dr. Babbitt was an Immunotherapy Consultant at Eligix, Inc. in Medford, MA from February 1999 through May 2000. Previously, Dr. Babbitt was at Cellcor, Inc. in Newton, MA, where he was the Director of Immunology Research from January 1991-July 1993, VP Research & Process Development from August 1993-June 1996, and VP R&D / QA & QC from July 1996-September 1998. Before joining Cellcor, Dr. Babbitt worked at Lipogen, Inc. in Knoxville, TN, where he was a Research Scientist/Program Manager from July 1986-June 1998, Director of Liposome Technology from July 1998-January 1990, and Group Director R&D from February 1990-November 1990. Dr. Babbitt received his M.A., B.S. in Industrial Engineering from Worcester Polytechnical Institute in 1975, his Ph.D. in Biochemistry from the University of Tennessee, Knoxville in 1984, and completed his Post Doctoral Studies in Cellular Immunology from 1985-1986 at Harvard Medical School, Boston, MA & Washington University Medical School, St. Louis, MO.
| 